ABIONYX Pharma SA (ABNX.PA)
EUR 1.25
(2.46%)
EUR 1.25
(2.46%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.29 Million EUR | -26.01% |
| 2022 | -3.98 Million EUR | 29.59% |
| 2021 | -5.83 Million EUR | -205.53% |
| 2020 | -2.32 Million EUR | -182.81% |
| 2019 | 1.8 Million EUR | 140.57% |
| 2018 | -6.26 Million EUR | -16.43% |
| 2017 | -5.8 Million EUR | 79.78% |
| 2016 | -26.95 Million EUR | -53.41% |
| 2015 | -17.29 Million EUR | -188.11% |
| 2014 | -6.77 Million EUR | 27.28% |
| 2013 | -9.27 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.29 Million EUR | 0.0% |
| 2023 Q4 | -561.5 Thousand EUR | -1.26% |
| 2023 FY | - EUR | -26.01% |
| 2023 Q1 | -1.07 Million EUR | 48.25% |
| 2023 Q2 | -2.66 Million EUR | -147.93% |
| 2023 Q3 | -554.5 Thousand EUR | 79.22% |
| 2022 Q3 | -793.5 Thousand EUR | 72.48% |
| 2022 Q2 | -2.88 Million EUR | -141.46% |
| 2022 Q1 | -1.19 Million EUR | 74.53% |
| 2022 Q4 | -2.08 Million EUR | -162.13% |
| 2022 FY | - EUR | 29.59% |
| 2021 Q2 | -2.95 Million EUR | -129.68% |
| 2021 Q3 | -1.67 Million EUR | 43.42% |
| 2021 Q4 | -4.68 Million EUR | -180.3% |
| 2021 FY | - EUR | -205.53% |
| 2021 Q1 | -1.28 Million EUR | 45.19% |
| 2020 FY | - EUR | -182.81% |
| 2020 Q4 | -2.34 Million EUR | -145.35% |
| 2020 Q3 | -957 Thousand EUR | 17.29% |
| 2020 Q2 | -1.15 Million EUR | -124.22% |
| 2020 Q1 | -516 Thousand EUR | 58.25% |
| 2019 FY | - EUR | 140.57% |
| 2019 Q1 | -719.5 Thousand EUR | 48.03% |
| 2019 Q4 | -1.23 Million EUR | -130.38% |
| 2019 Q2 | -1.79 Million EUR | -148.78% |
| 2019 Q3 | -536.5 Thousand EUR | 70.03% |
| 2018 Q2 | -1.48 Million EUR | 0.0% |
| 2018 Q1 | -1.48 Million EUR | 20.63% |
| 2018 FY | - EUR | -16.43% |
| 2018 Q4 | -1.38 Million EUR | 0.0% |
| 2018 Q3 | -1.38 Million EUR | 6.52% |
| 2017 FY | - EUR | 79.78% |
| 2017 Q3 | -1.86 Million EUR | -30.22% |
| 2017 Q4 | -1.86 Million EUR | 0.0% |
| 2017 Q1 | -1.43 Million EUR | 71.26% |
| 2017 Q2 | -1.43 Million EUR | 0.0% |
| 2016 Q2 | -7 Million EUR | 0.0% |
| 2016 Q4 | -4.98 Million EUR | 0.0% |
| 2016 Q3 | -4.98 Million EUR | 28.84% |
| 2016 Q1 | -7 Million EUR | -53.31% |
| 2016 FY | - EUR | -53.41% |
| 2015 FY | - EUR | -188.11% |
| 2015 Q1 | -3.13 Million EUR | -123.85% |
| 2015 Q3 | -4.57 Million EUR | -45.58% |
| 2015 Q2 | -3.13 Million EUR | 0.0% |
| 2015 Q4 | -4.57 Million EUR | 0.0% |
| 2014 Q1 | -1.58 Million EUR | 0.0% |
| 2014 Q3 | -1.4 Million EUR | 11.71% |
| 2014 FY | - EUR | 27.28% |
| 2014 Q4 | -1.4 Million EUR | 0.0% |
| 2014 Q2 | -1.58 Million EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIVAX Société Anonyme | -133.2 Million EUR | 97.53% |
| Adocia SA | -22.73 Million EUR | 85.527% |
| Aelis Farma SA | -6.34 Million EUR | 48.164% |
| Biophytis S.A. | -13.8 Million EUR | 76.166% |
| Advicenne S.A. | -6.24 Million EUR | 47.309% |
| genOway Société anonyme | 6.35 Million EUR | 151.805% |
| IntegraGen SA | -52.5 Thousand EUR | -6166.309% |
| Medesis Pharma S.A. | -3.84 Million EUR | 14.432% |
| Neovacs S.A. | -8.44 Million EUR | 61.063% |
| NFL Biosciences SA | -4.04 Million EUR | 18.751% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 4636.054% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -14.495% |
| Sensorion SA | -22.31 Million EUR | 85.256% |
| Theranexus Société Anonyme | -7.38 Million EUR | 55.464% |
| TME Pharma N.V. | -5.07 Million EUR | 35.134% |
| Valbiotis SA | -6.95 Million EUR | 52.696% |
| TheraVet SA | -517.33 Thousand EUR | -535.95% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 82.607% |
| argenx SE | -199.5 Million EUR | 98.351% |
| BioSenic S.A. | -6.79 Million EUR | 51.589% |
| Celyad Oncology SA | -7.76 Million EUR | 57.619% |
| DBV Technologies S.A. | -79.53 Million EUR | 95.863% |
| Galapagos NV | 51.03 Million EUR | 106.446% |
| Genfit S.A. | -28.05 Million EUR | 88.271% |
| GeNeuro SA | -14.31 Million EUR | 77.021% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 78.037% |
| Innate Pharma S.A. | -7.57 Million EUR | 56.585% |
| Inventiva S.A. | -101.84 Million EUR | 96.77% |
| MaaT Pharma SA | -19.74 Million EUR | 83.333% |
| MedinCell S.A. | -20.04 Million EUR | 83.588% |
| Nanobiotix S.A. | -34.01 Million EUR | 90.329% |
| Onward Medical N.V. | -35.23 Million EUR | 90.662% |
| Oryzon Genomics S.A. | -4.43 Million EUR | 25.79% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 85.859% |
| Oxurion NV | -16.72 Million EUR | 80.334% |
| Pharming Group N.V. | 4.98 Million EUR | 166.051% |
| Poxel S.A. | -12.17 Million EUR | 72.986% |
| GenSight Biologics S.A. | -21.73 Million EUR | 84.86% |
| Transgene SA | -27.02 Million EUR | 87.826% |
| Financière de Tubize SA | 184.57 Thousand EUR | 1882.512% |
| UCB SA | 1.26 Billion EUR | 100.259% |
| Valneva SE | -64.51 Million EUR | 94.901% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 88.396% |